Adeline Sadipe, PA-C

Adeline Sadipe practices at Pacific Neuropsychiatric Specialists Inc. in Costa Mesa, California.

Adeline Sadipe's NPI, 1942062757, was assigned on January 26, 2024. Adeline Sadipe holds California license PA63944.

Adeline Sadipe's primary practice is Pacific Neuropsychiatric Specialists Inc., at 3151 Airway Ave, Costa Mesa, CA 92626 in Orange County. The practice phone is (714) 545-5550.

Adeline Sadipe's primary practice is Pacific Neuropsychiatric Specialists Inc. in Costa Mesa, California. The medical group on file is Pacific Neuropsychiatric Specialists. Dmand AI also links Adeline Sadipe to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Adeline Sadipe practices. Vendor and product names are available with a free account.

Physician assistant is Adeline Sadipe's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Adeline Sadipe is licensed in California.

CMS data shows 165 Medicare services from Adeline Sadipe across 3 procedure codes in 2024, for 36 Medicare patients. Medicare paid $11,987 for them. Every service was in an office.

CMS counts 36 Medicare patients who saw Adeline Sadipe in 2024. The largest group is 65 to 74, with 15 patients. 75% of them have anxiety, and 75% have depression. 58% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Adeline Sadipe's median patient age at 41, with 64% women.

In 2024, Adeline Sadipe wrote 673 Medicare Part D claims for 83 patients. 90% of them were for generic drugs. CMS names the drug for 551 of them, across 20 drugs with 11 or more claims each, at $39,941 in total drug cost.

Adeline Sadipe accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Adeline Sadipe as offering telehealth.

CMS Open Payments shows 425 general payments to Adeline Sadipe from 24 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $1,528.